产品
编 号：F759516
产品类型
规格
价格
是否有货
结构图
CAS No: 658052-09-6
产品详情
生物活性：
Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer.
体内研究：
Mapatumumab (10 mg/kg; i.p. for three times) controls tumor growth when combined with irradiation.Animal Model:Colo205-xenograft–bearing NMRI (nu/nu) nude mice
Dosage:10 mg/kg
Administration:Intraperitoneal injection; 10 mg/kg; on days 1, 4, and 8
Result:Showed no significant differences when used alone, but when combined with irradiation (5×3 Gy, d1–5) showed a pronounced tumor regrowth-delay.
体外研究：
Mapatumumab (0.01-100 μg/mL; 4 h) shows no growth inhibition to Pediatric Preclinical Testing Program (PPTP) cell lines.Mapatumumab (1-100 ng/mL; 24 h) shows significant potentiation of cytotoxicity and synergy when combined with (epirubicin) EPI for bladder cancer cells.Mapatumumab (100 ng/mL; 12 h) induces significant cell apoptosis of T24, 253J and J82 cells with the combination of EPI (1 μg/mL).Mapatumumab (100 ng/mL; 6-24 h) significantly activates caspase-8, -9 and -3 with the combination of EPI (1 μg/mL).
Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer.
体内研究：
Mapatumumab (10 mg/kg; i.p. for three times) controls tumor growth when combined with irradiation.Animal Model:Colo205-xenograft–bearing NMRI (nu/nu) nude mice
Dosage:10 mg/kg
Administration:Intraperitoneal injection; 10 mg/kg; on days 1, 4, and 8
Result:Showed no significant differences when used alone, but when combined with irradiation (5×3 Gy, d1–5) showed a pronounced tumor regrowth-delay.
体外研究：
Mapatumumab (0.01-100 μg/mL; 4 h) shows no growth inhibition to Pediatric Preclinical Testing Program (PPTP) cell lines.Mapatumumab (1-100 ng/mL; 24 h) shows significant potentiation of cytotoxicity and synergy when combined with (epirubicin) EPI for bladder cancer cells.Mapatumumab (100 ng/mL; 12 h) induces significant cell apoptosis of T24, 253J and J82 cells with the combination of EPI (1 μg/mL).Mapatumumab (100 ng/mL; 6-24 h) significantly activates caspase-8, -9 and -3 with the combination of EPI (1 μg/mL).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备